ACS Medicinal Chemistry Letters
Page 4 of 5
(16)
(17)
Brown, A. C.; Parish, T. Dxr Is Essential in Mycobacterium
tuberculosis and Fosmidomycin Resistance Is Due to a Lack
of Uptake. BMC Microbiol. 2008, 8, n.p.
Masini, T.; Hirsch, A. K. H. Development of Inhibitors of
the 2C-Methyl-D-Erythritol 4-Phosphate (MEP) Pathway
Enzymes as Potential Anti-Infective Agents. J. Med. Chem.
2014, 57, 9740–9763.
Wang, X.; Dowd, C. S. The Methylerythritol Phosphate
Pathway: Promising Drug Targets in the Fight against Tu-
berculosis. ACS Infect. Dis. 2018, 4, 278–290.
Singh, N.; Cheve, G.; Avery, M. A.; McCurdy, C. R. Target-
ing the Methyl Erythritol Phosphate (MEP) Pathway for
Novel Antimalarial, Antibacterial and Herbicidal Drug Dis-
covery: Inhibition of 1-Deoxy-D-Xylulose-5-Phosphate Re-
ductoisomerase (DXR) Enzyme. Curr. Pharm. Des. 2007,
13, 1161–1177.
Ponaire, S.; Zinglé, C.; Tritsch, D.; Grosdemange-Billiard,
C.; Rohmer, M. Growth Inhibition of Mycobacterium
Smegmatis by Prodrugs of Deoxyxylulose Phosphate Reduc-
to-Isomerase Inhibitors, Promising Anti-Mycobacterial
Agents. Eur. J. Med. Chem. 2012, 51, 277–285.
Uh, E.; Jackson, E. R.; San Jose, G.; Maddox, M.; Lee, R.
E.; Lee, R. E.; Boshoff, H. I.; Dowd, C. S. Antibacterial and
Antitubercular Activity of Fosmidomycin, FR900098, and
Their Lipophilic Analogs. Bioorg. Med. Chem. Lett. 2011,
21, 6973–6976.
Brücher, K.; Gräwert, T.; Konzuch, S.; Held, J.; Lienau, C.;
Behrendt, C.; Illarionov, B.; Maes, L.; Bacher, A.; Wittlin,
S.; et al. Prodrugs of Reverse Fosmidomycin Analogues. J.
Med. Chem. 2015, 58, 2025–2035.
Wiesner, J.; Ortmann, R.; Jomaa, H.; Schlitzer, M. Double
Ester Prodrugs of FR900098 Display Enhanced In-Vitro
Antimalarial Activity. Arch. Pharm. (Weinheim) 2007, 340,
667–669.
Chofor, R.; Sooriyaarachchi, S.; Risseeuw, M. D. P.;
Bergfors, T.; Pouyez, J.; Johny, C.; Haymond, A.; Everaert,
A.; Dowd, C. S.; Maes, L.; et al. Synthesis and Bioactivity
of β-Substituted Fosmidomycin Analogues Targeting 1-
Deoxy-D-Xylulose-5-Phosphate Reductoisomerase. J. Med.
Chem. 2015, 58, 2988–3001.
Pradere, U.; Garnier-Amblard, E. C.; Coats, S. J.; Amblard,
F.; Schinazi, R. F. Synthesis of Nucleoside Phosphate and
Phosphonate Prodrugs. Chem. Rev. 2014, 114, 9154–9218.
Jessen, H. J.; Schulz, T.; Balzarini, J.; Meier, C. Bioreversi-
ble Protection of Nucleoside Diphosphates. Angew. Chem.
Int. Ed. 2008, 47, 8719–8722.
Weinschenk, L.; Schols, D.; Balzarini, J.; Meier, C. Nucleo-
side Diphosphate Prodrugs: Nonsymmetric DiPPro-
Nucleotides. J. Med. Chem. 2015, 58, 6114–6130.
Gollnest, T.; Dinis de Oliveira, T.; Rath, A.; Hauber, I.;
Schols, D.; Balzarini, J.; Meier, C. Membrane-Permeable
Triphosphate Prodrugs of Nucleoside Analogues. Angew.
Chem. Int. Ed. 2016, 55, 5255–5258.
Gollnest, T.; de Oliveira, T. D.; Schols, D.; Balzarini, J.;
Meier, C. Lipophilic Prodrugs of Nucleoside Triphosphates
as Biochemical Probes and Potential Antivirals. Nat. Com-
mun. 2015, 6, n.p.
Hostetler, K. Y. Alkoxyalkyl Prodrugs of Acyclic Nucleo-
side Phosphonates Enhance Oral Antiviral Activity and Re-
duce Toxicity: Current State of the Art. Antiviral Res. 2009,
82, A84–A98.
Garber, S. B.; Kingsbury, J. S.; Gray, B. L.; Hoveyda, A. H.
Efficient and Recyclable Monomeric and Dendritic Ru-
Based Metathesis Catalysts. J. Am. Chem. Soc. 2000, 122,
8168–8179.
Chatterjee, A. K.; Choi, T.-L.; Sanders, D. P.; Grubbs, R. H.
A General Model for Selectivity in Olefin Cross Metathesis.
J. Am. Chem. Soc. 2003, 125, 11360–11370.
REFERENCES
1
2
3
4
5
6
7
8
(1)
(2)
(3)
WHO
|
World
malaria
report
ort/en/ (accessed Mar 13, 2018).
WHO
cessed Mar 13, 2018).
Dondorp, A. M.; Nosten, F.; Yi, P.; Das, D.; Phyo, A. P.;
Tarning, J.; Lwin, K. M.; Ariey, F.; Hanpithakpong, W.;
Lee, S. J.; et al. Artemisinin Resistance in Plasmodium
falciparum Malaria. N. Engl. J. Med. 2009, 361, 455–467.
Lu, F.; Culleton, R.; Zhang, M.; Ramaprasad, A.; von
Seidlein, L.; Zhou, H.; Zhu, G.; Tang, J.; Liu, Y.; Wang, W.;
et al. Emergence of Indigenous Artemisinin-Resistant Plas-
modium falciparum in Africa. N. Engl. J. Med. 2017, 376,
991–993.
|
Tuberculosis
(ac-
(18)
(19)
9
(4)
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
(20)
(21)
(5)
(6)
Frank, A.; Groll, M. The Methylerythritol Phosphate Path-
way to Isoprenoids. Chem. Rev. 2017, 117, 5675–5703.
Murkin, A. S.; Manning, K. A.; Kholodar, S. A. Mechanism
and Inhibition of 1-Deoxy-D-Xylulose-5-Phosphate Reduc-
toisomerase. Bioorganic Chem. 2014, 57, 171–185.
Mac Sweeney, A.; Lange, R.; Fernandes, R. P. M.; Schulz,
H.; Dale, G. E.; Douangamath, A.; Proteau, P. J.; Oefner, C.
The Crystal Structure of E. Coli 1-Deoxy-D-Xylulose-5-
Phosphate Reductoisomerase in a Ternary Complex with the
Antimalarial Compound Fosmidomycin and NADPH Re-
veals a Tight-Binding Closed Enzyme Conformation. J. Mol.
Biol. 2005, 345, 115–127.
(7)
(22)
(23)
(24)
(8)
Mombo-Ngoma, G.; Remppis, J.; Sievers, M.; Zoleko, R.
M.; Endamne, L.; Kabwende, L.; Veletzky, L.; Nguyen, T.
T.; Groger, M.; Lötsch, F.; et al. Efficacy and Safety of
Fosmidomycin-Piperaquine as Non-Artemisinin-Based
Combination Therapy for Uncomplicated falciparum Malar-
ia - A Single-Arm, Age-de-Escalation Proof of Concept
Study in Gabon. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc.
Am. 2017, 66, 1823-1830.
(9)
Borrmann, S.; Adegnika, A. A.; Matsiegui, P.-B.; Issifou, S.;
Schindler, A.; Mawili-Mboumba, D. P.; Baranek, T.;
Wiesner, J.; Jomaa, H.; Kremsner, P. G. Fosmidomycin-
Clindamycin for Plasmodium falciparum Infections in Afri-
can Children. J. Infect. Dis. 2004, 189, 901–908.
(25)
(26)
(27)
(28)
(10)
Borrmann, S.; Adegnika, A. A.; Moussavou, F.; Oyakhi-
rome, S.; Esser, G.; Matsiegui, P.-B.; Ramharter, M.;
Lundgren, I.; Kombila, M.; Issifou, S.; et al. Short-Course
Regimens of Artesunate-Fosmidomycin in Treatment of Un-
complicated Plasmodium falciparum Malaria. Antimicrob.
Agents Chemother. 2005, 49, 3749–3754.
(11)
(12)
Murakawa, T.; Sakamoto, H.; Fukada, S.; Konishi, T.;
Nishida, M. Pharmacokinetics of Fosmidomycin, a New
Phosphonic Acid Antibiotic. Antimicrob. Agents Chemother.
1982, 21, 224–230.
Na-Bangchang, K.; Ruengweerayut, R.; Karbwang, J.;
Chauemung, A.; Hutchinson, D. Pharmacokinetics and
Pharmacodynamics of Fosmidomycin Monotherapy and
Combination Therapy with Clindamycin in the Treatment of
Multidrug Resistant falciparum Malaria. Malar. J. 2007, 6,
n.p.
(29)
(30)
(31)
(13)
(14)
Sakamoto, Y.; Furukawa, S.; Ogihara, H.; Yamasaki, M.
Fosmidomycin Resistance in Adenylate Cyclase Deficient
(Cya) Mutants of Escherichia coli. Biosci. Biotechnol.
Biochem. 2003, 67, 2030–2033.
Baumeister, S.; Wiesner, J.; Reichenberg, A.; Hintz, M.;
Bietz, S.; Harb, O. S.; Roos, D. S.; Kordes, M.; Friesen, J.;
Matuschewski, K.; et al. Fosmidomycin Uptake into Plas-
modium and Babesia-Infected Erythrocytes Is Facilitated by
Parasite-Induced New Permeability Pathways. PLoS ONE
2011, 6, e19334, n.p.
(32)
(33)
(15)
Nilsson, A. I.; Berg, O. G.; Aspevall, O.; Kahlmeter, G.;
Andersson, D. I. Biological Costs and Mechanisms of
Fosfomycin Resistance in Escherichia coli. Antimicrob.
Agents Chemother. 2003, 47, 2850–2858.
Verbrugghen, T.; Cos, P.; Maes, L.; Van Calenbergh, S.
Synthesis and Evaluation of α-Halogenated Analogues of 3-
(Acetylhydroxyamino)Propylphosphonic Acid (FR900098)
as Antimalarials. J. Med. Chem. 2010, 53, 5342–5346.
ACS Paragon Plus Environment